Acalabrutinib monotherapy for treatment of chronic lymphocytic leukaemia (ACE-CL-001): analysis of the Richter transformation cohort of an open-label, single-arm, phase 1–2 study

Toby A. Eyre(Oxford University Hospitals NHS Trust), Peter Hillmen(Leeds Teaching Hospitals NHS Trust), Jennifer R. Brown(Dana-Farber Cancer Institute), Raquel Izumi, John M. Pagel(University of Washington), Ahmed Hamdy(Pharmacyclics (United States)), Jean Cheung(AstraZeneca (United States)), Anna Schuh(University of Oxford), Min Hui Wang(AstraZeneca (United States)), Paolo Ghia(Vita-Salute San Raffaele University), William G. Wierda(University of Maryland, Baltimore), Yan Xu(AstraZeneca (United States)), John C. Byrd(University of Cincinnati), Priti Patel(AstraZeneca (United States)), Richard R. Furman(Cornell University)
The Lancet Haematology
November 1, 2021
10.1016/s2352-3026(21)00305-7
Cited by 60

Related Papers

Distinct types of diffuse large B-cell lymphoma identified by gene expression profiling
|Nature|2000|9.9k
Guidelines for the diagnosis and treatment of chronic lymphocytic leukemia: a report from the International Workshop on Chronic Lymphocytic Leukemia updating the National Cancer Institute–Working Group 1996 guidelines
|Blood|2008|3.2k
Targeting BTK with Ibrutinib in Relapsed Chronic Lymphocytic Leukemia
|New England Journal of Medicine|2013|2.2k
PI3K/AKT/mTOR signaling transduction pathway and targeted therapies in cancer
|Molecular Cancer|2023|1.9k
Targeting BCL2 with Venetoclax in Relapsed Chronic Lymphocytic Leukemia
|New England Journal of Medicine|2015|1.9k